Sophia Genetics expects biopharma to reach half of revenue long term and the United States 50% long term, while approaching $100 million of revenue, growing 25-plus percent, and targeting adjusted EBITDA profitability in the fourth quarter of next year.
SOPH · SOPHiA GENETICS SA
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $6.68
- Open
- $7.53
- Day range
- $6.67–7.65
- 52-week closing range
- $3.89–8.92
- Average volume, 30 days
- 690K
- Short interest
- 1.1M · 1.3% of shares · 2.6 days
- Short volume, last session
- 39%
- Last earnings
- Nov 3, 2026
- Price history
- Jul 2021 to Nov 2026
Up next
Latest documents
Sophia Genetics reported 25% revenue growth and expects 2026 revenue at the upper end of its $94 to $96 million guidance range. Adjusted EBITDA loss improved 31% to $6.1 million, with positive adjusted EBITDA expected in the second half of 2027.
SOPHiA GENETICS SA reported revenue of $24,267 thousand for the three months ended September 30, 2026, up from $19,462 thousand. Nine-month loss was $61,950 thousand, while cash and cash equivalents reached $93,652 thousand.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SOPH
this stock
SOPHiA GENETICS SA
|
$572.20M | +43.0% | — | — | 1.3% |
|
VEEV
Veeva Systems Inc
|
$42.57B | +17.8% | +28.1% | 43.0 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$12.74B | +70.9% | +28.2% | 34.8 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$10.87B | +0.9% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 11, 2026
- This year
- 16
Sophia Genetics expects biopharma to reach half of revenue long term and the United States 50% long term, while approaching $100 million of revenue, growing 25-plus percent, and targeting adjusted EBITDA profitability in the fourth quarter of next year.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SOPH | -15.0% | -5.3% | +33.9% | -12.5% | +43.0% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -9.6% | +1.0% | +39.5% | -7.2% | +38.1% |